Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Multiple Myeloma through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 36 active trials
25 drugs · 1,009 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 5 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Venetoclax | Phase 3 | Phase 3 | 10 | 4 | 3 | 25 | 0 | — | — | Oct 10, 2012 |
| Trametinib | Phase 3 | Phase 3 | 8 | 2 | 1 | 11 | 0 | — | — | Oct 30, 2013 |
| Etoposide | Phase 3 | Phase 3 | 7 | 3 | 6 | 29 | 0 | — | — | 1998-06 |
| Cisplatin | Phase 3 | Phase 3 | 5 | 1 | 4 | 14 | 0 | — | — | 1998-06 |
| Pembrolizumab | Phase 3 | Phase 3 | 4 | 2 | 2 | 26 | 0 | — | — | Nov 22, 2013 |
| Sirolimus | Phase 3 | Phase 3 | 4 | 2 | 1 | 22 | 0 | — | — | 2004-11 |
| Dabrafenib | Phase 3 | Phase 3 | 4 | 1 | 1 | 5 | 0 | — | — | Aug 17, 2015 |
| Nivolumab | Phase 3 | Phase 3 | 3 | 1 | 1 | 23 | 0 | — | — | Aug 2, 2012 |
| Pegfilgrastim | Phase 3 | Phase 3 | 2 | 1 | 2 | 6 | 0 | — | — | 2003-12 |
| Filgrastim | Phase 3 | Phase 3 | 1 | 0 | 5 | 50 | 0 | — | — | 1998-08 |
| Methotrexate | Phase 3 | Phase 3 | 1 | 0 | 1 | 15 | 0 | — | — | 1988-03 |
| Cytarabine | Phase 3 | Phase 3 | 1 | 1 | 2 | 8 | 0 | — | — | 1998-08 |
| Aspirin | Phase 3 | Phase 3 | 1 | 0 | 3 | 7 | 0 | — | — | 2007-01 |
| Cobimetinib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Nov 13, 2017 |
| Vemurafenib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Apr 12, 2012 |
| Bendamustine | Phase 3 | Phase 3 | 0 | 0 | 1 | 29 | 0 | — | — | 2008-02 |
| Vorinostat | Phase 3 | Phase 3 | 0 | 0 | 1 | 14 | 0 | — | — | 2005-09 |
| Carmustine | Phase 3 | Phase 3 | 0 | 0 | 3 | 11 | 0 | — | — | 1994-01 |
| Vincristine | Phase 3 | Phase 3 | 0 | 0 | 4 | 8 | 0 | — | — | 1994-01 |
| Perifosine | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2005-12 |
| Prednisolone | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2008-07 |
| Masitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2005-02 |
| Tanespimycin | Phase 3 | Phase 3 | 0 | 0 | 2 | 2 | 0 | — | — | 2007-08 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2006-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.